Print

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

https://www.facingourrisk.org/research-clinical-trials/study/166/dostarlimab-plus-carboplatin-paclitaxel-versus-placebo-plus-carboplatin-paclitaxel-for-recurrent-or-primary-advanced-endometrial-cancer-ruby

Clinicaltrials.gov identifier:
NCT03981796 (https://clinicaltrials.gov/show/NCT03981796)


Metastatic endometrial cancer

Study Contact Information:

For additional information, please contact: US GSK Clinical Trials Call Center by phone:  877-379-3718 or by email: [email protected]          

About the Study

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of the immunotherapy dostarlimab (Jemperli), the targeted therapy niraparib (Zejula) and chemotherapy works compared with chemotherapy alone. NOTE: This study is no longer enrolling people. 

This Study is Open To:

NOTE: This study is no longer enrolling people. 

This Study is Not Open To:

NOTE: This study is no longer enrolling people. 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.